<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1102256877
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ARBITEN PLUS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        160,25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        32.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jordan Sweden Medical and Sterilization Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 679]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-DAWAA MEDICAL SERVICES CO. LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ARBITEN PLUS Film Coated Tablets contain two active substances called Valsartan and Hydrochlorothiazide.</p><p>Both of these substances help to control high blood pressure (hypertension).</p><p>&bull; Valsartan belongs to a class of medicines known as &ldquo;angiotensin II receptor antagonists&rdquo;, which help to control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase. Valsartan works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered.</p><p>&bull;Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics (also known as &ldquo;water tablets&rdquo;).Hydrochlorothiazide increases urine output, which also lowers blood pressure.</p><p>ARBITEN PLUS is used to treat high blood pressure which is not adequately controlled by a single substance alone.</p><p>High blood pressure increases the workload of the heart and arteries. If not treated, it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure or kidney failure.</p><p>High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take ARBITEN PLUS:</p><p>&bull; if you are allergic (hypersensitive) to Valsartan, Hydrochlorothiazide, sulphonamide derivatives (substances chemically related to Hydrochlorothiazide) or to any of the other ingredients of ARBITEN PLUS.</p><p>&bull; if you are more than 3 months pregnant (it is also better to avoid ARBITEN PLUS in early pregnancy &ndash; see pregnancy section).</p><p>&bull; if you have severe liver disease, destruction of the small bile ducts within the liver (biliary cirrhosis) leading to the buildup of bile in the liver (cholestasis).</p><p>&bull; if you have severe kidney disease.</p><p>&bull; if you are unable to produce urine (anuria).</p><p>&bull; if you are treated with an artificial kidney.</p><p>&bull; if the level of potassium or sodium in your blood is lower than normal, or if the level of calcium in your blood is higher than normal despite treatment.</p><p>&bull; if you have gout.</p><p>&bull; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine called aliskiren.</p><p>If any of the above applies to you, do not take this medicine and speak to your doctor.</p><p>Take special care with ARBITEN PLUS:</p><p>&bull;if you are taking potassium-sparing medicines, potassium supplements, salt substitutes containing potassium or other medicines that increase the amount of potassium in your blood such as heparin. Your doctor may need to check the amount of potassium in your blood regularly.</p><p>&bull; if you have low levels of potassium in your blood.</p><p>&bull; if you have diarrhoea or severe vomiting.</p><p>&bull; if you are taking high doses of water tablets (diuretics).</p><p>&bull; if you have severe heart disease.</p><p>&bull; if you are suffering from heart failure or have experienced a heart attack. Follow your doctor&rsquo;s instruction for the starting dose carefully. Your doctor may also check your kidney function.</p><p>&bull; if you suffer from a narrowing of the kidney artery.</p><p>&bull; if you have recently received a new kidney.</p><p>&bull; if you suffer from hyperaldosteronism. This is a disease in which your adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of ARBITEN PLUS is not recommended.</p><p>&bull; if you have liver or kidney disease.</p><p>&bull; if you have ever experienced swelling of the tongue and face caused by an allergic reaction called angioedema when taking another drug (including ACE inhibitors), tell your doctor. If these symptoms occur when you are taking ARBITEN PLUS, stop taking ARBITEN PLUS immediately and never take it again. See also, &ldquo;Possible side effects&rdquo;.</p><p>&bull; if you have fever, rash and joint pain, which may be signs of systemic lupus erythematosus (SLE, a so-called autoimmune disease).</p><p>&bull; if you have diabetes, gout, high levels of cholesterol or triglycerides in your blood.</p><p>&bull; if you have had allergic reactions with the use of other blood pressure-lowering agents of this class (angiotensin II receptor antagonists) or if you have allergy or asthma.</p><p>&bull; if you experience a decrease in vision or eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to a week of taking ARBITEN PLUS. This can lead to permanent vision loss, if not treated. If you earlier have had a penicillin or sulphonamide allergy you can be at higher risk of developing this.</p><p>&bull; it may cause increased sensitivity of the skin to sun.</p><p>&bull; the use of ARBITEN PLUS in children and adolescents below the age of 18 years is not recommended.</p><p>&bull;you must tell your doctor if you think you are (or might become) pregnant. ARBITEN PLUS is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>&bull; Combination therapy of ACEI and ARB drugs may cause an increased risk of hyperkalaemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with kidney problems.</p><p>If any of these apply to you, talk to your doctor.</p><p>Taking other medicines:</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>The effect of the treatment can be influenced if ARBITEN PLUS is taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or in some cases to stop taking one of the medicines. This especially applies to the following medicines:</p><p>&bull; lithium, a medicine used to treat some types of psychiatric diseases.</p><p>&bull; medicines or substances that may increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p>&bull; medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, carbenoxolone, amphotericin or penicillin G.</p><p>&bull; some antibiotics (rifamycin group), a drug used to protect against transplant rejection (ciclosporin) or an antiretroviral drug used to treat HIV/AIDS infection (ritonavir). These drugs may increase the effect of ARBITEN PLUS.</p><p>&bull; medicines that may induce &ldquo;torsades de pointes&rdquo; (irregular heart beat), such as antiarrhythmics (medicines used to treat heart problems) and some antipsychotics.</p><p>&bull; medicines that may reduce the amount of sodium in your blood, such as antidepressants, antipsychotics, antiepileptics.</p><p>&bull; medicines for the treatment of gout, such as allopurinol, probenecid, sulfinpyrazone.</p><p>&bull; therapeutic vitamin D and calcium supplements.</p><p>&bull; medicines for the treatment of diabetes (oral agents such as metformin or insulins).</p><p>&bull; other medicines to lower your blood pressure including methyldopa, ACE inhibitors (such as enalapril, lisinopril, etc.) or aliskiren.</p><p>&bull; medicines to increase blood pressure, such as noradrenaline or adrenaline.</p><p>&bull; digoxin or other digitalis glycosides (medicines used to treat heart problems).</p><p>&bull; medicines that may increase blood sugar levels, such as diazoxide or beta blockers.</p><p>&bull; cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide.</p><p>&bull; pain killers such as non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 inhibitors (Cox-2 inhibitors) and acetylsalicylic acid &gt; 3 g.</p><p>&bull; muscle relaxing medicines, such as tubocurarine.</p><p>&bull; anti-cholinergic medicines (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson&#39;s disease and as an aid to anaesthesia).</p><p>&bull; amantadine (medicine used to treat Parkinson&rsquo;s disease and also used to treat or prevent certain illnesses caused by viruses).</p><p>&bull; cholestyramine and colestipol (medicines used mainly to treat high levels of lipids in the blood).</p><p>&bull; ciclosporin, a medicine used for organ transplant to avoid organ rejection.</p><p>&bull; alcohol, sleeping pills and anaesthetics (medicines with sleeping or painkilling effect used for example during surgery).</p><p>&bull; iodine contrast media (agents used for imaging examinations).</p><p>Taking ARBITEN PLUS with food and drinks:</p><p>You can take ARBITEN PLUS with or without food.</p><p>Avoid taking alcohol until you have talked to your doctor. Alcohol may make your blood pressure fall more and/or increase the risk of you becoming dizzy or feeling faint.</p><p>Pregnancy and breast-feeding:</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&bull; You must tell your doctor if you think that you are (or might become) pregnant.</p><p>Your doctor will normally advise you to stop taking ARBITEN PLUS before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of ARBITEN PLUS. ARBITEN PLUS is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</p><p>&bull; Tell your doctor if you are breast-feeding or about to start breast-feeding.</p><p>ARBITEN PLUS is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p>Driving and using machines:</p><p>Before you drive a vehicle, use tools or operate machines or carry out other activities that require concentration, make sure you know how ARBITEN PLUS affects you. Like many other medicines used to treat high blood pressure, ARBITEN PLUS may occasionally cause dizziness and affect the ability to concentrate.</p><p>Important information about some of the ingredients of ARBITEN PLUS:</p><p>None.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take ARBITEN PLUS exactly as your doctor has told you. This will help you to get the best results and lower the risk of side effects. You should check with your doctor or pharmacist if you are not sure.</p><p>People with high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with your doctor even if you are feeling well.</p><p>Your doctor will tell you exactly how many tablets of ARBITEN PLUS to take. Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.</p><p>&bull; The usual dose of ARBITEN PLUS is one Film Coated Tablet per day.</p><p>&bull; Do not change the dose or stop taking the tablets without consulting your doctor.</p><p>&bull; The medicine should be taken at the same time each day, usually in the morning.</p><p>&bull; You can take ARBITEN PLUS with or without food.</p><p>&bull; Swallow the Film Coated Tablets with a glass of water.</p><p>If you take more ARBITEN PLUS than you should:</p><p>If you experience severe dizziness and/or fainting, lie down and contact your doctor immediately.</p><p>If you have accidentally taken too many tablets, contact your doctor, pharmacist or hospital.</p><p>If you forget to take ARBITEN PLUS:</p><p>If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the dose you missed.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking ARBITEN PLUS:</p><p>Stopping your treatment with ARBITEN PLUS may cause your high blood pressure to get worse. Do not stop taking your medicine unless your doctor tells you to.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, ARBITEN PLUS can cause side effects, although not everybody gets them.</p><p>These side effects may occur with certain frequencies, which are defined as follows:</p><p>&bull; very common: affects more than 1 user in 10.</p><p>&bull; common: affects 1 to 10 users in 100.</p><p>&bull; uncommon: affects 1 to 10 users in 1,000.</p><p>&bull; rare: affects 1 to 10 users in 10,000.</p><p>&bull; very rare: affects less than 1 user in 10,000.</p><p>&bull;&nbsp; not known: frequency cannot be estimated from the available data.</p><p>Some side effects can be serious and need immediate medical attention:</p><p>You should see your doctor immediately if you experience symptoms of angioedema, such as:</p><p>&bull; swollen face, tongue or pharynx</p><p>&bull; difficulty in swallowing</p><p>&bull; hives and difficulties in breathing</p><p>If you get any of these symptoms, stop taking ARBITEN PLUS and contact your doctor straight away (see also section &ldquo;Take special care with ARBITEN PLUS&rdquo;).</p><p>Other side effects include:</p><p>Uncommon:</p><p>&bull; cough.&nbsp;&nbsp;&nbsp; &bull; low blood pressure.&nbsp;&nbsp;&nbsp; &bull; light-headedness.</p><p>&bull; dehydration (with symptoms of thirst, dry mouth and tongue, infrequent urination, dark colored urine, dry skin).</p><p>&bull; muscle pain.&nbsp;&nbsp;&nbsp;&nbsp; &bull; tiredness.&nbsp;&nbsp;&nbsp; &bull; tingling or numbness.</p><p>&bull; blurred vision.&nbsp;&nbsp;&nbsp; &bull; noises (e.g. hissing, buzzing) in ears.</p><p>Very rare:</p><p>&bull; dizziness.&nbsp; &nbsp;&nbsp;&bull; diarrhoea.&nbsp;&nbsp;&nbsp; &bull; joint pain.</p><p>Not known:</p><p>&bull; breathing difficulty.&nbsp;&nbsp;&nbsp; &bull; severely decreased urine output.</p><p>&bull; low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and / or convulsions in severe cases).</p><p>&bull; low level of potassium in the blood (sometimes with muscle weakness, muscle spasms, abnormal heart rhythm).</p><p>&bull; low level of white cells in the blood (with symptoms such as fever, skin infections, sore throat or mouth ulcers due to infections, weakness).</p><p>&bull; the level of bilirubin increased in blood (which can, in severe cases, trigger yellow skin and eyes).</p><p>&bull; the level of blood urea nitrogen and creatinine increased in blood (which can indicate abnormal kidney function).</p><p>&bull; the level of uric acid in blood increased (which can, in severe cases, trigger gout).</p><p>&bull; syncope (fainting).</p><p>The following side effects have been reported with products containing Valsartan or hydrochlorothiazide alone:</p><p>Valsartan:</p><p>Uncommon:</p><p>&bull; spinning sensation.&nbsp;&nbsp;&nbsp; &bull; abdominal pain.</p><p>Not known:</p><p>&bull; skin rash with or without itching together with some of the following signs or symptoms: fever, joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms.</p><p>&bull; rash, purplished-red spots, fever, itching (symptoms of inflammation of blood vessels).</p><p>&bull; low level of blood platelets (sometimes with unusual bleeding or bruising).</p><p>&bull; high level of potassium in the blood (sometimes with muscle spasms, abnormal heart rhythm).</p><p>&bull; allergic reactions (with symptoms such as rash, itching, hives, difficulty breathing or swallowing, dizziness).</p><p>&bull; swelling mainly of the face and throat; rash; itching.</p><p>&bull; elevation of liver function values.</p><p>&bull; the level of haemoglobin decreased and the percentage of red cells decreased in the blood (which both can, in severe cases, trigger an anaemia).</p><p>&bull; kidney failure.</p><p>&bull; low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and/or convulsions in severe cases).</p><p>Hydrochlorothiazide:</p><p>Very common:</p><p>&bull; low level of potassium in the blood.&nbsp;&nbsp;&nbsp; &bull; increase of lipids in the blood.</p><p>Common:</p><p>&bull; low level of sodium in the blood.&nbsp;&nbsp;&nbsp; &bull; low level of magnesium in the blood.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&bull; high level of uric acid in the blood.</p><p>&bull; itchy rash and other types of rash.&nbsp;&nbsp;&nbsp; &bull; reduced appetite.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&bull; mild nausea and vomiting.</p><p>&bull; dizziness, fainting on standing up.&nbsp;&nbsp;&nbsp;</p><p>&bull; inability to achieve or maintain erection.</p><p>Rare:</p><p>&bull; swelling and blistering of the skin (due to increased sensitivity to sun).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&bull; high level of calcium in the blood.&nbsp;&nbsp;&nbsp; &bull; high level of sugar in the blood.</p><p>&bull; sugar in the urine.&nbsp;&nbsp;&nbsp; &bull; worsening of diabetic metabolic state.</p><p>&bull; constipation, diarrhoea, discomfort of the stomach or bowels, liver disorders which can occur together with yellow skin and eyes.</p><p>&bull; irregular heart beat.&nbsp;&nbsp;&nbsp; &bull; headache.&nbsp;&nbsp;&nbsp; &bull; sleep disturbances.</p><p>&bull; sad mood (depression).</p><p>&bull; low level of blood platelets (sometimes with bleeding or bruising underneath the skin).</p><p>&bull; dizziness.&nbsp;&nbsp;&nbsp; &bull; tingling or numbness.&nbsp;&nbsp;&nbsp; &bull; vision disorder.</p><p>Very rare:</p><p>&bull; inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever (vasculitis).</p><p>&bull; rash, itching, hives, difficulty breathing or swallowing, dizziness (hypersensitivity reactions).</p><p>&bull; severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal necrolysis).</p><p>&bull; facial rash, joint pain, muscle disorder, fever (lupus erythematosus).</p><p>&bull; severe upper stomach pain (pancreatitis).</p><p>&bull; difficulty breathing with fever, coughing, wheezing, breathlessness (respiratory distress including pneumonitis and pulmonary oedema).</p><p>&bull; fever, sore throat, more frequent infections (agranulocytosis).</p><p>&bull; pale skin, tiredness, breathlessness, dark urine (haemolytic anaemia).</p><p>&bull; fever, sore throat or mouth ulcers due to infections (leucopenia).</p><p>&bull; confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraemic alkalosis).</p><p>Not known:</p><p>&bull; weakness, bruising and frequent infections (aplastic anemia).</p><p>&bull; severely decreased urine output (possible signs of renal disorder or renal failure).</p><p>&bull; decrease in vision or pain in your eyes due to high pressure (possible signs of acute angle-closure glaucoma).</p><p>&bull; rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (possible signs of erythema multiforme).</p><p>&bull; muscle spasm.&nbsp;&nbsp;&nbsp; &bull; fever (pyrexia).&nbsp;&nbsp;&nbsp; &bull; weakness (asthenia).</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.</p><p>&bull; Do not use ARBITEN PLUS after the expiry date which is stated on the label and carton after EXP.</p><p>&bull; This medicinal product does not require any special storage conditions.</p><p>&bull; Do not use any ARBITEN PLUS pack that is damaged or shows signs of tampering.</p><p>&bull; Store below 30oC</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ARBITEN PLUS 80/12.5 contains 80mg of Valsartan and 12.5mg of Hydrochlorothiazide.</p><p>ARBITEN PLUS 160/12.5 contains 160mg of Valsartan and 12.5mg of Hydrochlorothiazide.</p><p>ARBITEN PLUS 160/25 contains 160mg of Valsartan and 25mg of Hydrochlorothiazide.</p><p>The other ingredients are: Microcrystalline Cellulose, Povidone, Crospovidone, Sodium Lauryl Sulphate, Silicified Microcrystalline Cellulose, Talc, Magnesium Stearate, Hydroxy Propyl Methyl Cellulose, (Hydroxy Propyl Methyl Cellulose &amp; Yellow Iron Oxide).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form: Film Coated Tablets.
Pack size: 30 Film Coated Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jordan Sweden Medical and Sterilization Company (Joswe-medical)</p><p>P.O. Box 851831 Amman 11185 Jordan</p><p>E-mail: joswe@go.com.jo</p><p>www.joswe.com</p><p>Tel: +962 6 5859765, +962 6 5728327</p><p>Fax: +962 6 5814526, +962 6 5728326</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:</p><p>Al-Dawaa Medical Services Co. Ltd.</p><p>P.O. Box 4326 Al Khobar 31952</p><p>www.al-dawaa.com</p><p>Tel: +966 13 845 0824</p><p>Fax: +966 13 859 5629</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 08/2015; Revision number R1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي أقراص أربتين بلاص على مادتين فعالتين هما فالسارتان وهيدروكلوروثيازيد. تساعد هاتين المادتين في السيطرة على ارتفاع ضغط الدم.</p><p dir="RTL">&bull; فالسارتان ينتمي إلى فئة من الأدوية تعرف باسم &quot;مضادات مستقبلات أنجيوتنسين II &quot;، والتي تساعد في السيطرة على ارتفاع ضغط الدم. أنجيوتنسين II هو عبارة عن مادة في الجسم تعمل على تحفيز انقباض الأوعية الدموية، مما يؤدي إلى ارتفاع ضغط الدم. يعمل فالسارتان عن طريق تثبيط أنجيوتنسين II، وهذا يؤدي إلى استرخاء الأوعية الدموية وانخفاض ضغط الدم.</p><p dir="RTL">&bull; هيدروكلوروثيازيد ينتمي إلى مجموعة من الأدوية تسمى مدرات البول الثيازيد (المعروف أيضا باسم &quot;أقراص الماء&quot;). هيدروكلوروثيازيد يزيد من كمية البول، الذي يساعد ايضا على انخفاض ضغط الدم.</p><p dir="RTL">تستعمل أقراص أربتين بلاص لعلاج ارتفاع ضغط الدم الذي لا تتحقق السيطرة الكافية عليها باستعمال مادة واحدة فقط.</p><p dir="RTL">ارتفاع ضغط الدم يزيد من الجهد على القلب والشرايين. إذا لم يتم علاجه، فإنه يؤدي إلى تلف الأوعية الدموية في الدماغ والقلب والكلى، ويمكن أن يؤدي إلى سكتة دماغية، وقصور عضلة القلب أو الكلى.</p><p dir="RTL">ارتفاع ضغط الدم يزيد من مخاطر التعرض لنوبات قلبية. العمل على تخفيض ضغط الدم لديك إلى المستويات الطبيعية يقلل من خطر الإصابة بهذه الاضطرابات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول أربتين بلاص:</p><p dir="RTL">&bull; إذا كنت تعاني من الحساسية لكل من فالسارتان أو هيدروكلوروثيازايد أو مشتقات السلفوناميد (مواد لها علاقة بهيدروكلوروثيازايد كيميائياً) أو لأي مكونات أخرى في هذا الدواء.</p><p dir="RTL">&bull; إذا كنت حامل لأكثر من ثلاثة أشهر (و يفضل أيضاً عدم تناول أربتين بلاص خلال المراحل الأولى من الحمل&nbsp; &ndash; راجع فقرة الحمل).</p><p dir="RTL">&bull; إذا كنت تعاني من مرض حاد في الكبد، وتليف الكبد الصفراوي مما يؤدي إلى تراكم الصفراء في الكبد.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض حاد في الكلى.</p><p dir="RTL">&bull; إذا كنت تعاني من عدم القدرة على التبول.</p><p dir="RTL">&bull; إذا كنت تتعالج بالكلية الاصطناعية (الديلزة).</p><p dir="RTL">&bull; إذا كانت مستويات الدم من البوتاسيوم أو الصوديوم أقل من المعدل الطبيعي أو إذا كان مستوى الكالسيوم في الدم أعلى من المعدل الطبيعي على الرغم من العلاج.</p><p dir="RTL">&bull; إذا كان لديك النقرس.</p><p dir="RTL">&bull; إذا كان لديك مرض السكري أو اختلال وظائف الكلى وتتعالج باستخدام&nbsp; دواء لخفض ضغط الدم يدعى أليسكيرين.</p><p dir="RTL">إذا كان أي مما ذكر أعلاه ينطبق عليك، لا تتناول هذا الدواء و قم باستشارة طبيبك.</p><p dir="RTL">التحذيرات و الاحتياطات:</p><p dir="RTL">&bull; إذا كنت تتناول الأدوية الحافظة للبوتاسيوم أو مكملات البوتاسيوم أو بدائل الأملاح التي تحتوي على البوتاسيوم أو أي أدوية أخرى تعمل على زيادة كمية البوتاسيوم في الدم مثل الهيبارين. قد يحتاج طبيبك لفحص كمية البوتاسيوم في الدم بشكل منتظم.</p><p dir="RTL">&bull; إذا كنت تعاني من انخفاض مستويات البوتاسيوم في الدم.</p><p dir="RTL">&bull; إذا كنت تعاني من إسهال أو قيء حاد.</p><p dir="RTL">&bull; إذا كنت تتناول جرعات عالية من أقراص الماء (مدرات البول).</p><p dir="RTL">&bull; إذا كنت تعاني من مرض قلبي حاد.</p><p dir="RTL">&bull; إذا كنت تعاني من قصور في القلب أو تعرضت لنوبة قلبية. اتبع تعليمات الطبيب بعناية للجرعة الابتدائية. قد يتحقق طبيبك أيضاً من وظائف الكلى.</p><p dir="RTL">&bull; إذا كنت تعاني من تضيق شرايين الكلى.</p><p dir="RTL">&bull; إذا خضعت مؤخراً لزراعة الكلى.</p><p dir="RTL">&bull; إذا كنت تعاني من فرط إفراز الألدوستيرون. و هو عبارة عن مرض في الغدد الكظرية ينتج عنه إفراز كمية كبيرة من هرمون الألدوستيرون.&nbsp; إذا كان ذلك ينطبق عليك، لا يوصى باستعمال أقراص أربتين بلاص.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض في الكبد أو الكلى.</p><p dir="RTL">&bull; أخبر طبيبك إذا كنت تعرضت مسبقاً لتورم اللسان والوجه الناجم عن رد الفعل التحسسي الذي يدعى وذمة وعائية عند تعاطي دواء آخر (بما في ذلك مثبطات ACE). في حال حدوث هذه الأعراض عند تناولك أربتين بلاص، يجب التوقف فورا عن تناوله&nbsp; وعدم استخدامه مرة أخرى. (راجع فقرة الآثار الجانبية المحتملة).</p><p dir="RTL">&bull; إذا كنت تعاني من الحمى و الطفح و ألم المفاصل التي تعتبر علامات للذأب الحمامي الجهازي (ويدعى أيضاً مرض المناعة الذاتية).</p><p dir="RTL">&bull; إذا كنت تعاني من داء السكري أو النقرس أو مستويات مرتفعة من الكوليسترول أو الدهون في الدم.</p><p dir="RTL">&bull; إذا حصل لديك تفاعلات تحسسية عند تناولك لعوامل أخرى مضادة لارتفاع ضغط الدم من هذه الفئة (مضادات مستقبلات أنجيوتنسن II) أو إذا كنت تعاني من الحساسية أو الربو.</p><p dir="RTL">&bull;&nbsp; قد يزيد هذا الدواء من حساسية الجلد لأشعة الشمس.</p><p dir="RTL">&bull; الأطفال و المراهقون: لا يوصى باستعمال أقراص مغلفة غشائياً أربتين بلاص للأطفال و المراهقين الأقل من 18 سنة.</p><p dir="RTL">&bull; يجب عليك أن تخبري الطبيب إذا كنت تعتقدين بأنك حامل أو تخططين لذلك.&nbsp; لا يوصى بتناول أقراص مغلفة غشائياً أربتين بلاص خلال المراحل الأولى من الحمل، و يجب عدم تناوله إذا كنت حامل لأكثر من ثلاثة أشهر، حيث من الممكن أن يؤذي الجنين عند استعماله بعد الشهر الثالث من الحمل. (راجع فقرة الحمل)</p><p dir="RTL">&bull;الاستعمال المتزامن لمثبطات الأنزيم المحول للأنجيوتنسين (ACE) و مضادات مستقبلات الأنجيوتنسين (ARB) قد يؤدي إلى زيادة احتمالية حدوث ارتفاع مستوى البوتاسيوم و تراجع وظائف الكلى و هبوط الضغط. لذلك يجب عدم استعمالهما بشكل متزامن و خاصة المرضى الذين لديهم مشاكل في الكلى.</p><p dir="RTL">إذا كان أي مما ذكر أعلاه ينطبق عليك، قم باستشارة طبيبك.</p><p dir="RTL">تناول أدوية أخرى:</p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أي أدوية أخرى، بما في ذلك الأدوية التي تم تناولها بدون وصفة طبية.</p><p dir="RTL">قد يتأثر العلاج إذا تم تناول أربتين بلاص بشكل متزامن مع بعض الأدوية الأخرى. قد يكون من الضروري تغيير الجرعة واتخاذ احتياطات أخرى أو في بعض الحالات التوقف عن تناول أحد الأدوية. ينطبق ذلك خصوصاً على الأدوية التالية:</p><p dir="RTL">&bull; الليثيوم، وهو دواء يستخدم لعلاج أنواع معينة من الأمراض النفسية.</p><p dir="RTL">&bull; الأدوية أو المواد التي قد تزيد من كمية البوتاسيوم في الدم. وتشمل مكملات البوتاسيوم أو بدائل الأملاح التي تحتوي على البوتاسيوم والأدوية الحافظة للبوتاسيوم و الهيبارين.</p><p dir="RTL">&bull; الأدوية التي قد تقلل من كمية البوتاسيوم في الدم، مثل مدرات البول (أقراص الماء)، الستيرويدات القشرية، الملينات، كربينوكسولون، الأمفوتريسين أو البنسلين G.</p><p dir="RTL">&bull; بعض المضادات الحيوية (مجموعة ريفاميسن)، وهو دواء يستخدم لحماية ضد رفض الزرع (سيكلوسبورين) أو دواء المضاد للفيروسات المستخدمة لعلاج العدوى بفيروس نقص المناعة البشرية / الإيدز (ريتونافير). هذه الأدوية قد تزيد من تأثير أربتين بلاص.</p><p dir="RTL">&bull; الأدوية التي ربما تتسبب في عدم انتظام ضربات القلب، مثل الأدوية المستخدمة لعلاج مشاكل القلب وبعض مضادات الذهان.</p><p dir="RTL">&bull; الأدوية التي قد تقلل من كمية الصوديوم في الدم، مثل مضادات الاكتئاب، مضادات الذهان، مضادات الصرع.</p><p dir="RTL">&bull; الأدوية المستخدمة في علاج النقرس، مثل ألوبيورينول، بروبينسيد، سلفينبيريزون.</p><p dir="RTL">&bull; فيتامين D العلاجي و مكملات الكالسيوم.</p><p dir="RTL">&bull; الأدوية المستخدمة في علاج مرض السكري (الأدوية التي تؤخذ عن طريق الفم مثل ميتفورمين أو الأنسولين).</p><p dir="RTL">&bull; الأدوية الأخرى المستخدمة لخفض ضغط الدم بما في ذلك ميثيل دوبا، مثبطات ACE (مثل إنالابريل، ليزينوبريل،...) أو أليسكيرين.</p><p dir="RTL">&bull; الأدوية المستخدمة لزيادة ضغط الدم، مثل النورأدرينالين أو الأدرينالين.</p><p dir="RTL">&bull; الديجوكسين أو جليكوسيدات الديجيتال الأخرى (الأدوية المستخدمة لعلاج مشاكل القلب).</p><p dir="RTL">&bull; الأدوية التي قد تزيد من مستويات السكر في الدم، مثل ديازوكسيد أو حاصرات بيتا.</p><p dir="RTL">&bull; الأدوية السامة للخلايا (التي تستخدم لعلاج السرطان)، مثل الميثوتركسيت أو سيكلوفوسفاميد.</p><p dir="RTL">&bull; مسكنات الألم مثل الأدوية غير الستيرويدية المضادة للالتهابات، بما في ذلك مثبطات COX-2 وحامض الأسيتيل سلسلك &gt; 3 غرام.</p><p dir="RTL">&bull; الأدوية الراخية للعضلات ، مثل توبوكورارين.</p><p dir="RTL">&bull; الأدوية المضادة للكولين (الأدوية المستخدمة لعلاج مجموعة مختلفة من الأمراض مثل تقلصات المعدة والأمعاء، تشنج المثانة البولية ، والربو، ودوار الحركة، وتشنجات العضلات، ومرض الباركنسون وكعامل مساعد في التخدير).</p><p dir="RTL">&bull; أمانتادين (دواء يستخدم لعلاج مرض باركنسون وأيضا يستخدم لعلاج أو منع بعض الأمراض التي تسببها الفيروسات).</p><p dir="RTL">&bull; الكولسترامين و كوليستيبول (أدوية تستخدم لعلاج ارتفاع مستويات الدهون في الدم).</p><p dir="RTL">&bull; سيكلوسبورين، وهو دواء يستخدم عند زرع الأعضاء لتجنب رفض العضو .</p><p dir="RTL">&bull; الكحول و الحبوب المنومة و المسكنات ( الأدوية التي لها تأثير منوم أو مسكن المستخدمة أثناء الجراحة).</p><p dir="RTL">&bull; اليود المستخدم لفحص التصوير.</p><p dir="RTL">تناول أربتين بلاص مع الطعام والشراب:</p><p dir="RTL">يمكنك أن تتناول أربتين بلاص مع أو بدون الطعام.</p><p dir="RTL">تجنب تناول الكحول لحين استشارة الطبيب. الكحول قد يسبب انخفاض ضغط الدم أكثر و/أو قد يزيد من خطر الاصابة بالدوار أو الشعور بالإغماء.</p><p dir="RTL">الحمل والإرضاع:</p><p dir="RTL">إسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL">&bull; اسألي طبيبك إذا كنت حاملاً أو تخططين للإنجاب، بالعادة سينصحك بالتوقف عن تناول أربتين بلاص قبل أن&nbsp; تصبحي حامل أو في حال علمك بأنك حامل، وسيقوم باستبدال أربتين بلاص بدواء آخر. لا يوصى بتناول أربتين بلاص خلال المرحلة الأولى من الحمل، ويجب عدم تناوله بعد الشهر الثالث من الحمل، لأنه قد يسبب ضرر جسيم لطفلك إذا تم استخدامه بعد الشهر الثالث من الحمل.</p><p dir="RTL">&bull; أخبر طبيبك إذا كنت مرضعة أو على وشك البدء بالإرضاع</p><p dir="RTL">لا يوصى بتناول أربتين بلاص للأمهات المرضعات، وقد يختار الطبيب علاج آخر بالنسبة لك إذا كنت ترغبين بالإرضاع، وخصوصاً&nbsp; إذا كان طفلك حديث الولادة أو خديج.</p><p dir="RTL">القيادة وتشغيل الآلات:</p><p dir="RTL">يجب التأكد من كيفية تفاعلك مع أربتين بلاص قبل قيادة المركبات أو استخدام الأدوات أو تشغيل الآلات أو القيام بأي أنشطة أخرى تتطلب التركيز. كما هو الحال مع العديد من الأدوية التي تستخدم لعلاج ارتفاع ضغط الدم، أحيانا قد يسبب أربتين بلاص الدوخة و يؤثر على القدرة على التركيز.</p><p dir="RTL">معلومات هامة عن بعض مكونات أربتين بلاص:</p><p dir="RTL">لا يوجد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماً تناول دوائك كما أخبرك الطبيب أو الصيدلاني.&nbsp; سيساعد ذلك في الحصول على أفضل النتائج و تقليل خطورة الآثار الجانبية.&nbsp; إذا لم تكن متأكداً،&nbsp; قم باستشارة طبيبك أو الصيدلاني. غالباً الأشخاص المصابون بارتفاع ضغط الدم لا يلاحظون أي علامة لظهور هذه المشكلة.&nbsp; معظمهم قد يشعرون بالوضع الطبيعي لهم. هذا يجعل الأمر أكثر أهمية بالنسبة لك للحفاظ على مواعيدك مع الطبيب حتى لو كنت على ما يرام.</p><p dir="RTL">سيخبرك الطبيب عن كمية الجرعة التي يجب عليك تناولها من أقراص أربتين بلاص اعتماداً على استجابتك للعلاج، قد يصف لك الطبيب جرعة أعلى أو أقل.</p><p dir="RTL">&bull;&nbsp; الجرعة الموصى بها من أقراص مغلفة غشائياً أربتين بلاص هي قرص واحد يومياً.</p><p dir="RTL">&bull; لا تقم بتغيير الجرعة أو التوقف عن تناول الأقراص دون استشارة الطبيب.</p><p dir="RTL">&bull;&nbsp; يجب تناول هذا الدواء في نفس الوقت من كل يوم، غالباً في الصباح.</p><p dir="RTL">&bull; يمكن تناول أقراص مغلفة غشائياً أربتين بلاص مع أو دون تناول الطعام.</p><p dir="RTL">&bull; تناول القرص مع كوب من الماء.</p><p dir="RTL">إذا تناولت أقراص أربتين بلاص أكثر مما يجب:</p><p dir="RTL">إذا شعرت بدوار حاد و/أو الإغماء، استلقي و قم بالاتصال بطبيبك فوراً.&nbsp; إذا تناولت بالخطأ أكثر مما يجب، قم بالاتصال بطبيبك أو الصيدلاني أو المستشفى.</p><p dir="RTL">إذا نسيت تناول جرعة أربتين بلاص:</p><p dir="RTL">إذا نسيت تناول الجرعة، تناولها حال تذكرك لها. عموماً، لا تتناول الجرعة التي نسيتها إذا اقترب موعد الجرعة التالية.&nbsp; لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL">إذا توقفت عن تناول أقراص أربتين بلاص:</p><p dir="RTL">قد يسبب التوقف عن العلاج بأقراص أربتين بلاص ازدياد سوء ارتفاع ضغط الدم.&nbsp; لا تتوقف عن تناول دوائك ما لم يطلب منك الطبيب ذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة اضافية عن استعمال هذا الدواء، قم باستشارة الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب أربتين بلاص آثار جانبية على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">قد تحدث هذه الآثار الجانبية بتكرارات مختلفة، والتي تعرف كما يلي:</p><p dir="RTL">&bull; شائعة جداً: تؤثر على أكثر من 1 من كل&nbsp; 10 مستخدمين.</p><p dir="RTL">&bull; شائعة: تؤثر على 1 إلى 10 من كل 100 مستخدم.</p><p dir="RTL">&bull; غير شائعة: تؤثر على 1 إلى 10 من كل 1000 مستخدم.</p><p dir="RTL">&bull; نادرة: تؤثر على 1 إلى 10 من كل 10000 مستخدم.</p><p dir="RTL">&bull; نادرة جداً: تؤثر على أقل من 1 من كل 10000 مستخدم.</p><p dir="RTL">&bull; غير معروفة:لا يمكن تقدير تكرار حدوثها من المعلومات المتوفرة.</p><p dir="RTL">بعض الآثار الجانبية يمكن أن تكون خطيرة و تحتاج إلى عناية طبية فورية:</p><p dir="RTL">يجب مراجعة الطبيب فوراً إذا حدثت لك أعراض وذمة وعائية، مثل :</p><p dir="RTL">&bull; تورم الوجه واللسان أو البلعوم.</p><p dir="RTL">&bull; صعوبة في البلع.</p><p dir="RTL">&bull; شرى و صعوبات في التنفس.</p><p dir="RTL">اذا كان لديك أي من هذه الأعراض، توقف عن تناول أربتين بلاص واتصل بطبيبك على الفور (راجع أيضاً &quot;التحذيرات و الاحتياطات&quot;).</p><p dir="RTL">وتشمل الآثار الجانبية الأخرى:</p><p dir="RTL">غير شائعة:</p><p dir="RTL">&bull; السعال.&nbsp;&nbsp;&nbsp;&nbsp; &bull; انخفاض ضغط الدم.&nbsp;&nbsp;&nbsp;&nbsp; &bull; الشعور بالدوارن.</p><p dir="RTL">&bull; الجفاف (مع أعراض العطش وجفاف الفم واللسان، وتبول غير متكرر والبول داكن اللون، وجفاف الجلد).</p><p dir="RTL">&bull; آلام في العضلات.&nbsp;&nbsp;&nbsp;&nbsp; &bull; التعب.&nbsp;&nbsp;&nbsp;&nbsp; &bull; وخز أو خدر.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&bull; عدم وضوح الرؤية.&nbsp;&nbsp;&nbsp;&nbsp; &bull; الضوضاء (مثل الهسهسة، طنين) في الأذن.</p><p dir="RTL">نادرة جداً:</p><p dir="RTL">&bull; الدوخة.&nbsp;&nbsp;&nbsp;&nbsp; &bull; الإسهال.&nbsp;&nbsp;&nbsp;&nbsp; &bull; آلام المفاصل.</p><p dir="RTL">غير معروفة:</p><p dir="RTL">&bull; صعوبة في التنفس.&nbsp;&nbsp;&nbsp;&nbsp; &bull; انخفاض كبير في كمية البول.</p><p dir="RTL">&bull; انخفاض مستوى الصوديوم في الدم (والذي يمكن أن يؤدي إلى التعب والارتباك و ارتعاش العضلات و/أو تشنجات في الحالات الشديدة).</p><p dir="RTL">&bull; انخفاض مستوى البوتاسيوم في الدم (في بعض الأحيان مع ضعف العضلات و تشنجات العضلات و ضربات قلب غير طبيعية).</p><p dir="RTL">&bull; انخفاض مستوى الخلايا البيضاء في الدم (مع أعراض مثل الحمى والتهابات الجلد والتهاب الحلق أو تقرحات في الفم بسبب الالتهابات والشعور بالضعف).</p><p dir="RTL">&bull; ارتفاع مستوى البيليروبين في الدم (والذي قد يسبب في الحالات الشديدة إلى اصفرار البشرة والعيون)</p><p dir="RTL">&bull;ارتفاع مستوى نيتروجين اليوريا والكرياتينين في الدم (والذي قد يشير إلى اضطراب في وظيفة الكلى).</p><p dir="RTL">&bull;ارتفاع مستوى حمض اليوريك في الدم (والذي قد يسبب في الحالات الشديدة النقرس).</p><p dir="RTL">&bull; الإغماء (الغثيان).</p><p dir="RTL">وقد تم الإبلاغ عن الآثار الجانبية التالية مع المستحضرات التي تحتوي على فالسارتان أو هيدروكلوروثيازيد لوحده:</p><p dir="RTL">فالسارتان:</p><p dir="RTL">غير شائعة:</p><p dir="RTL">&bull; الإحساس بالدوران.&nbsp;&nbsp;&nbsp;&nbsp; &bull; ألم في البطن.</p><p dir="RTL">غير معروفة:</p><p dir="RTL">&bull; طفح جلدي مع أو دون حكة، يرافق ذلك بعض من العلامات أو الأعراض التالية: الحمى وآلام المفاصل وآلام في العضلات وتضخم الغدد الليمفاوية و/أو أعراض تشبه الانفلونزا.</p><p dir="RTL">&bull; الطفح الجلدي وبقع حمراء أرجوانية والحمى والحكة (أعراض التهاب الأوعية الدموية).</p><p dir="RTL">&bull; انخفاض مستوى الصفائح الدموية (وأحيانا مع نزيف غير عادي أو كدمات).</p><p dir="RTL">&bull; ارتفاع مستوى البوتاسيوم في الدم (في بعض الأحيان قد يصاحبه تشنجات في العضلات واضراب ضربات القلب).</p><p dir="RTL">&bull; الحساسية (مع أعراض مثل الطفح الجلدي والحكة و الشرى و صعوبة في التنفس أو البلع والدوخة).</p><p dir="RTL">&bull; تورم خاصة في الوجه والحلق و طفح الجلدي و حكة.</p><p dir="RTL">&bull; ارتفاع قيم وظائف الكبد.</p><p dir="RTL">&bull; انخفاض مستوى الهيموغلوبين ونسبة خلايا الدم الحمراء في الدم (والذي قد يؤدي كل منهما في الحالات الشديدة إلى فقر الدم).</p><p dir="RTL">&bull; الفشل الكلوي.</p><p dir="RTL">&bull; انخفاض مستوى الصوديوم في الدم (والذي يمكن أن يؤدي إلى التعب والارتباك وارتعاش العضلات و/أو تشنجات في الحالات الشديدة).</p><p dir="RTL">هيدروكلوروثيازيد:</p><p dir="RTL">شائعة جداً:</p><p dir="RTL">&bull; انخفاض مستوى البوتاسيوم في الدم.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; ارتفاع نسبة الدهون في الدم.</p><p dir="RTL">شائعة:</p><p dir="RTL">&bull; انخفاض مستوى الصوديوم في الدم.&nbsp;&nbsp;&nbsp;&nbsp; &bull; انخفاض مستوى المغنيسيوم في الدم.</p><p dir="RTL">&bull; ارتفاع مستوى حمض اليوريك في الدم.&nbsp;&nbsp;&nbsp;&nbsp; &bull; طفح جلدي مع حكة وغيرها من أنواع الطفح الجلدي.</p><p dir="RTL">&bull; انخفاض الشهية.&nbsp;&nbsp;&nbsp;&nbsp; &bull; الغثيان والقيء بشكل متوسط.</p><p dir="RTL">&bull; الدوخة و الإغماء عند الوقوف.&nbsp;&nbsp;&nbsp;&nbsp; &bull; عدم القدرة على تحقيق أو الحفاظ على الانتصاب.</p><p dir="RTL">نادرة:</p><p dir="RTL">&bull; تورم و ظهور تقرحات في الجلد (بسبب زيادة الحساسية لأشعة الشمس).</p><p dir="RTL">&bull; ارتفاع مستوى الكالسيوم في الدم.&nbsp;&nbsp;&nbsp;&nbsp; &bull; ارتفاع مستوى السكر في الدم.</p><p dir="RTL">&bull; السكر في البول.&nbsp;&nbsp;&nbsp;&nbsp; &bull; تدهور حالة التمثيل الغذائي لمرضى السكري.</p><p dir="RTL">&bull; الإمساك والإسهال وعدم الراحة في المعدة أو الأمعاء&nbsp; واضطرابات الكبد التي يمكن أن تحدث مع اصفرار البشرة والعيون.</p><p dir="RTL">&bull; عدم انتظام ضربات القلب.&nbsp;&nbsp;&nbsp;&nbsp; &bull; الصداع.&nbsp;&nbsp;&nbsp;&nbsp; &bull; اضطرابات النوم.&nbsp;&nbsp;&nbsp;&nbsp; &bull; مزاج حزين (الاكتئاب).</p><p dir="RTL">&bull; انخفاض مستوى الصفائح الدموية (و أحيانا مع نزيف أو كدمات تحت الجلد)</p><p dir="RTL">&bull; الدوخة.&nbsp;&nbsp;&nbsp;&nbsp; &bull; وخز أو خدر.&nbsp;&nbsp;&nbsp;&nbsp; &bull; اضطراب الرؤية.</p><p dir="RTL">نادرة جداً:</p><p dir="RTL">&bull; التهاب الأوعية الدموية مع أعراض مثل الطفح الجلدي والبقع الأرجوانية الحمراء والحمى (التهاب الأوعية الدموية).</p><p dir="RTL">&bull; الطفح الجلدي والحكة و الشرى وصعوبة في التنفس أو البلع والدوخة (تفاعلات فرط الحساسية).</p><p dir="RTL">&bull; أمراض الجلد الشديدة التي تسبب الطفح الجلدي و احمرار الجلد و تقرحات الشفاه والعينين أو الفم و تقشير الجلد و الحمى (انحلال البشرة السمي).</p><p dir="RTL">&bull; طفح جلدي في الوجه وآلام المفاصل واضطرابات العضلات و الحمى (الذئبة الحمامية).</p><p dir="RTL">&bull; آلام حادة&nbsp; في الجزء العلوي من المعدة (التهاب البنكرياس).</p><p dir="RTL">&bull; صعوبة في التنفس مع حمى وسعال وصفير عند التنفس و ضيق التنفس بما في ذلك التهاب رئوي ووذمة رئوية.</p><p dir="RTL">&bull; الحمى و التهاب الحلق و التهابات متكررة (ندرة المحببات).</p><p dir="RTL">&bull; شحوب البشرة و التعب وضيق التنفس والبول الداكن (فقر الدم الانحلالي).</p><p dir="RTL">&bull; الحمى و التهاب الحلق أو تقرحات في الفم بسبب الالتهابات (نقص الكريات البيض).</p><p dir="RTL">&bull; الارتباك و التعب و ارتعاش العضلات و التشنج و سرعة التنفس.</p><p dir="RTL">غير معروفة:</p><p dir="RTL">&bull; ضعف وكدمات والتهابات متكررة (فقر الدم اللاتنسجي).</p><p dir="RTL">&bull; انخفاض شديد في&nbsp; كمية البول (علامات محتملة لاضطرابات وظائف الكلى أو الفشل الكلوي).</p><p dir="RTL">&bull; انخفاض في الرؤية أو ألم في عينيك بسبب الضغط العالي.</p><p dir="RTL">&bull; الطفح الجلدي و احمرار الجلد و تقرحات في الشفاه والعينين أو الفم و تقشير الجلد و الحمى (علامات محتملة من الحمامي عديدة الأشكال).</p><p dir="RTL">&bull; تشنج العضلات.&nbsp;&nbsp;&nbsp;&nbsp; &bull; الحمى.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; ضعف (الوهن).</p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي في حال أصبحت أي من الآثار الجانبية خطيرة، أو إذا لاحظت أي آثار جانبية غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; يحفظ بعيداً عن متناول الأطفال.</p><p dir="RTL">&bull; لا تستخدم أربتين بلاص بعد انتهاء فترة الصلاحية&nbsp; المذكورة على اللاصق الداخلي و العبوة الخارجية.</p><p dir="RTL">&bull; لا يتطلب هذا المنتج الدوائي أي ظروف تخزين خاصة.</p><p dir="RTL">&bull; لا تستخدم أربتين بلاص عند ملاحظة أي علامة تلف فيه.</p><p>&bull; يخزن في درجة حرارة أقل من 30 درجة مئوية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; أربتين بلاص 80/12.5&nbsp; يحتوي على 80 ملجم فالسارتان و 12.5 ملجم هيدروكلوروثيازيد.</p><p dir="RTL">&bull; أربتين بلاص 160/12.5 يحتوي على 160 ملجم فالسارتان و 12.5 ملجم هيدروكلوروثيازيد.</p><p dir="RTL">&bull; أربتين بلاص 160/25 يحتوي على 160 ملجم فالسارتان و 25 ملجم هيدروكلوروثيازيد.</p><p dir="RTL">المكونات الأخرى هي: ميكروكريستالين السليولوز، بوفيدون، كروس بوفيدون، كبريتات لوريل الصوديوم، سيلسفيد ميكروكريستالين سيليلوز، تالك، مغنيسيوم ستيرات، هيدروكسي بروبيل ميثيل سليلوز، (هيدروكسي بروبيل ميثيل سليلوز وأصفر أكسيد الحديد).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشكل الصيدلاني: أقراص مغلفة غشائياً.</p><p dir="RTL">حجم العبوة: 30 قرص مغلفة غشائياً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة الأردنية السويدية للمنتجات الطبية و التعقيم.</p><p dir="RTL">صندوق بريد 851831&nbsp; عمان 11185&nbsp; الأردن</p><p dir="RTL">الايميل: joswe@go.com.jo</p><p dir="RTL">www.joswe.com</p><p dir="RTL">هاتف:&nbsp; +962 6 5859765 ، +962 6 5728327</p><p dir="RTL">فاكس: +962 6 5814526، +962 6 5728326</p><p dir="RTL">للحصول على أي معلومات عن هذا المنتج الدوائي، يرجى الاتصال بالوكيل المحلي للشركة المالكة لحق التسويق:</p><p dir="RTL">شركة الدواء للخدمات الطبية المحدودة</p><p dir="RTL">صندوق بريد 4326 الخبر 31952</p><p dir="RTL">www.al-dawaa.com</p><p dir="RTL">هاتف:&nbsp;&nbsp;&nbsp; +966 13 845 0824</p><p dir="RTL">فاكس: +966 13 859 5629</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في  08/2015، رقم المراجعة R1 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arbiten Plus 80/12.5 Film Coated Tablet.
Arbiten Plus 160/12.5 Film Coated Tablet.
Arbiten Plus 160/25 Film Coated Tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arbiten Plus 80/12.5 Film Coated Tablet: each film coated tablet contain valsartan 80mg and Hydrochlorothiazide 12.5mg
Arbiten Plus 160/12.5 Film Coated Tablet: each film coated tablet contain valsartan 160mg and Hydrochlorothiazide 12.5mg
Arbiten Plus 160/25 Film Coated Tablet: each film coated tablet contain valsartan 160mg and Hydrochlorothiazide 25mg
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension in adults.</p><p>Arbiten Plus fixed-dose combination is indicated in patients whose blood pressure is not adequately controlled on valsartan or hydrochlorothiazide monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>The recommended dose of Arbiten Plus 80/12.5mg or 160/12.5mg or 160/25mg is one film coated tablet once daily. Dose titration with the individual components is recommended. In each case, up- titration of individual components to the next dose should&nbsp;be followed in order to reduce the risk of hypotension and other adverse events. When clinically appropriate direct change from monotherapy to the fixed combination may be considered in patients whose blood pressure is not adequately controlled on valsartan or hydrochlorothiazide monotherapy, provided the recommended dose titration sequence for the individual components is followed.</p><p>The clinical response to Arbiten Plus should be evaluated after initiating therapy and if blood pressure remains uncontrolled, the dose may be increased by increasing either one of the components to a maximum dose of Arbiten Plus 320 mg/25 mg. The antihypertensive effect is substantially present within 2 weeks. In most patients, maximal effects are observed within 4 weeks. However, in some patients, 4-8 weeks treatment may be required. This should be taken into account during dose-titration.</p><p>Method of administration</p><p>Arbiten Plus can be taken with or without food and should be administered with water.</p><p>Special populations</p><p>Renal impairment</p><p>No dose adjustment is required for patients with mild to moderate renal impairment (Glomerular Filtration Rate (GFR) &ge; 30 ml/min). Due to the hydrochlorothiazide component, Arbiten Plus is contraindicated in patients with severe renal impairment (GFR &lt; 30 mL/min) and anuria (see sections 4.3, 4.4 and 5.2). Concomitant use of valsartan with aliskiren is contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73 m2) (see section 4.3).</p><p>Diabetes Mellitus</p><p>Concomitant use of valsartan with aliskiren is contraindicated in patients with diabetes mellitus (see section 4.3).</p><p>Hepatic impairment</p><p>In patients with mild to moderate hepatic impairment without cholestasis the dose of valsartan should not exceed 80 mg (see section 4.4). No adjustment of the hydrochlorothiazide dose is required for patients with mild to moderate hepatic impairment. Due to the valsartan component, Arbiten Plus is contraindicated in patients with severe hepatic impairment or with biliary cirrhosis and cholestasis (see sections 4.3, 4.4 and 5.2).</p><p>Elderly</p><p>No dose adjustment is required in elderly patients.</p><p>Paediatric patients</p><p>Arbiten Plus is not recommended for use in children below the age of 18 years due to a lack of data on safety and efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to valsartan, hydrochlorothiazide, other sulfonamide-derived medicinal products or to any of the excipients.
- Second and third trimester of pregnancy (section 4.4 and 4.6).
- Severe hepatic impairment, biliary cirrhosis and cholestasis. 
- Severe renal impairment (creatinine clearance < 30 ml/min), anuria. 
- Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia. 
- Concomitant use of angiotensin receptor antagonists (ARBs) – including valsartan – or of angiotensin-converting-enzyme inhibitors (ACEIs) with aliskiren in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73m2) (see sections 4.4 and 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>WARNING: FETAL TOXICITY<br />See full prescribing information for complete boxed warning<br />When pregnancy is detected, discontinue Valsartan/Hydrochlorothiazide as soon as possible.<br />Drugs that act directly on the renin-angiotensin system can cause injury or death to the developing fetus.</td></tr></tbody></table><p>Serum electrolyte changes</p><p>Valsartan</p><p>Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.</p><p>Hydrochlorothiazide Hypokalaemia has been reported under treatment with thiazide diuretics, including hydrochlorothiazide. Frequent monitoring of serum potassium is recommended. Treatment with thiazide diuretics, including hydrochlorothiazide has been associated with hyponatraemia and hypochloraemic alkalosis. Thiazides, including hydrochlorothiazide increase the urinary excretion of magnesium, which may result in hypomagnesaemia. Calcium excretion is decreased by thiazide diuretics. This may result in hypercalcaemia. As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.</p><p>Sodium, and/or volume-depleted patients</p><p>Patients receiving thiazide diuretics, including hydrochlorothiazide, should be observed for clinical signs of fluid or electrolyte imbalance.</p><p>In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with Arbiten Plus. Sodium and/or volume depletion should be corrected before starting treatment with Arbiten Plus.</p><p>Patients with severe chronic heart failure or other conditions with stimulation of the renin-angiotensin-aldosterone-system</p><p>In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia, and in rare cases with acute renal failure and/or death. Evaluation of patients with&nbsp;heart failure or post-myocardial infarction should always include assessment of renal function. The use of Arbiten Plus in patients with severe chronic heart failure has not been established. Hence it cannot be excluded that because of the inhibition of the renin-angiotensin-aldosterone system the application of Arbiten Plus as well may be associated with impairment of the renal function. Arbiten Plus should not be used in these patients.</p><p>Renal artery stenosis</p><p>Arbiten Plus should not be used to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis of the artery to a solitary kidney, since blood urea and serum creatinine may increase in such patients.</p><p>Primary hyperaldosteronism</p><p>Patients with primary hyperaldosteronism should not be treated with Arbiten Plus as their renin-angiotensin system is not activated.</p><p>Aortic and mitral valve stenosis, hypertrophic obstructive cardiomyopathy</p><p>As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).</p><p>Renal impairment</p><p>No dosage adjustment is required for patients with renal impairment with a creatinine clearance &gt; 30 ml/min (see section 4.2). Periodic monitoring of serum potassium, creatinine and uric acid levels is recommended when Arbiten Plus is used in patients with renal impairment. The concomitant use of ARBs &ndash; including valsartan &ndash; or of ACEIs with aliskiren is contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73m<sup>2</sup>) (see sections 4.3 and 4.5).</p><p>Kidney transplantation</p><p>There is currently no experience on the safe use of Arbiten Plus in patients who have recently undergone kidney transplantation.</p><p>Hepatic impairment</p><p>In patients with mild to moderate hepatic impairment without cholestasis, Arbiten Plus should be used with caution (see sections 4.2 and 5.2). Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.</p><p>History of angioedema</p><p>Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported in patients treated with valsartan; some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Arbiten Plus should be immediately discontinued in patients who develop angioedema, and Arbiten Plus should not be re-administered (see section 4.8).</p><p>Systemic lupus erythematosus</p><p>Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.</p><p>Other metabolic disturbances</p><p>Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.</p><p>Thiazides may reduce urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcaemia may be evidence of underlying hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p>Photosensitivity</p><p>Cases of photosensitivity reactions have been reported with thiazides diuretics (see section 4.8). If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.</p><p>Pregnancy</p><p>Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>General</p><p>Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.</p><p>Acute Angle-Closure Glaucoma</p><p>Hydrochlorothiazide, a sulfonamide, has been associated with an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to week of a drug initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatment may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p>Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS) Hypotension, syncope, stroke, hyperkalaemia, and changes in renal function (including acute renal failure) have been reported in susceptible individuals, especially if combining medicinal products that affect this system. Dual blockade of the renin-angiotensin-aldosterone system by combining aliskiren with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) is therefore not recommended.</p><p>The use of aliskiren in combination with Arbiten Plus is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions related to both valsartan and hydrochlorothiazide</p><p>Concomitant use not recommended</p><p>Lithium</p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors and thiazide, including hydrochlorothiazide. Due&nbsp;to the lack of experience with concomitant use of valsartan and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p>Concomitant use requiring caution</p><p>Other antihypertensive agents</p><p>Arbiten Plus may increase the effects of other agents with antihypertensive properties (e.g. guanethidine, methyldopa, vasodilators, ACEI, ARBs, beta-blockers, calcium channel blockers and DRIs).</p><p>Pressor amines (e.g. noradrenaline, adrenaline)</p><p>Possible decreased response to pressor amines. The clinical significance of this effect is uncertain and not sufficient to preclude their use.</p><p>Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid (&gt;3 g/day), and non-selective NSAIDs</p><p>NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of Arbiten Plus and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</p><p>Interactions related to valsartan</p><p>Dual blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACEIs, or aliskiren</p><p>Caution is required while co-administering ARBs, including valsartan, with other agents blocking the RAAS such as ACEIs or aliskiren (see section 4.4).&nbsp;</p><p>Concomitant use of angiotensin receptor antagonists (ARBs) &ndash; including valsartan &ndash; or of angiotensin-converting-enzyme inhibitors (ACEIs) with aliskiren in patients with diabetes mellitus or renal impairment (GFR &lt; 60 mL/min/1.73m<sup>2</sup>) is contraindicated (see section 4.3).</p><p>Concomitant use not recommended</p><p>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels. If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised.</p><p>Transporters</p><p>In vitro data indicates that valsartan is a substrate of the hepatic uptake transporter OATP1B1/OATP1B3 and the hepatic efflux transporter MRP2. The clinical relevance of this finding is unknown. Co-administration of inhibitors of the uptake transporter (eg. rifampin, ciclosporin) or efflux transporter (eg. ritonavir) may increase the systemic exposure to valsartan. Exercise appropriate care when initiating or ending concomitant treatment with such drugs.</p><p>No interaction</p><p>In drug interaction studies with valsartan, no interactions of clinical significance have been found with valsartan or any of the following substances: cimetidine, warfarin,furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide. Digoxin and indomethacin could interact with the hydrochlorothiazide component of Arbiten Plus (see interactions related to hydrochlorothiazide).</p><p>Interactions related to hydrochlorothiazide</p><p>Concomitant use requiring caution</p><p>Medicinal products affecting serum potassium level The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic diuretics, corticosteroids, laxatives, ACTH, amphotericin, carbenoxolone, penicillin G, salicylic acid and derivatives. If these medicinal products are to be prescribed with the hydrochlorothiazide-valsartan combination, monitoring of potassium plasma levels is advised (see section 4.4).</p><p>Medicinal products that could induce torsades de pointes</p><p>Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce torsades de pointes, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.</p><p>Medicinal products affecting serum sodium level</p><p>The hyponatraemic effect of diuretics may be intensified by concomitant administration of drugs such as antidepressants, antipsychotics, antiepileptics, etc. Caution is advised in long-term administration of these drugs.</p><p>Digitalis glycosides</p><p>Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects favouring the onset of digitalis-induced cardiac arrhythmias (see section 4.4).</p><p>Calcium salts and vitamin D</p><p>Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type diuretics with calcium salts may cause hypercalcaemia in patients pre-disposed for hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D-mediated conditions) by increasing tubular calcium reabsorption.</p><p>Antidiabetic agents (oral agents and insulin)</p><p>Thiazides may alter glucose tolerance. Dose adjustment of the antidiabetic medicinal product may be necessary.</p><p>Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p>Beta blockers and diazoxide</p><p>Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazide diuretics, including&nbsp;hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</p><p>Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)</p><p>Dose adjustment of uricosuric medications may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase of dosage of probenecid or sulfinpyrazone may be necessary. Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.</p><p>Anticholinergic agents and other medicinal products affecting gastric motility</p><p>The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, it is anticipated that prokinetic drugs such as cisapride may decrease the bioavailability of thiazide-type diuretics.</p><p>Amantadine</p><p>Thiazides, including hydrochlorothiazide, may increase the risk of adverse effects caused by amantadine.</p><p>Ion exchange resins</p><p>Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 h before or 4-6 h after the administration of resins would potentially minimise the interaction.</p><p>Cytotoxic agents</p><p>Thiazides, including hydrochlorothiazide, may reduce renal excretion of cytotoxic agents (e.g. cyclophosamide, methotrexate) and potentiate their myelosuppressive effects. Non-depolarising skeletal muscle relaxants (e.g. tubocurarine) Thiazides, including hydrochlorothiazide, potentiate the action of skeletal muscle relaxants such as curare derivatives.</p><p>Ciclosporin</p><p>Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.</p><p>Alcohol, barbiturates or narcotics</p><p>Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation activity) may potentiate orthostatic hypotension.</p><p>Methyldopa</p><p>There have been isolated reports of haemolytic anaemia in patients receiving concomitant treatment with methyldopa and hydrochlorothiazide.</p><p>Iodine contrast media</p><p>In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of the iodine product. Patients should be rehydrated before the administration</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>Valsartan</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during first trimester of pregnancy (see section 4.4). The use of AIIRAs is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</td></tr></tbody></table><p>When pregnancy is detected, discontinue Valsartan/Hydrochlorothiazide as soon as possible.<br />Drugs that act directly on the renin-angiotensin system can cause injury or death to the&nbsp;developing fetus.</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Inhibitors (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.</p><p>AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also section 5.3). Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also section 4.3 and 4.4).Hydrochlorothiazide There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p>Lactation</p><p>No information is available regarding the use of valsartan during breastfeeding. Hydrochlorothiazide is excreted in human milk. Therefore the use of Arbiten Plus during breast feeding is not recommended. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect of Arbiten Plus, on the ability to drive and use machines have been performed. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions reported in clinical trials and laboratory findings occurring more frequently with valsartan plus hydrochlorothiazide versus placebo and individual postmarketing reports are presented below according to system organ class. Adverse reactions known to occur with each component given individually but which have not been seen in clinical trials may occur during treatment with valsartan/ hydrochlorothiazide.</p><p>Adverse drug reactions are ranked by frequency, the most frequent first, using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare(&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated&nbsp;from the available data). Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><p>Table 1. Frequency of adverse reactions with valsartan/hydrochlorothiazide<br />Metabolism and nutrition disorders<br />Uncommon&nbsp; &nbsp;Dehydration</p><p>Nervous system disorders<br />Very rare&nbsp; Dizziness<br />Uncommon&nbsp; Paraesthesia<br />Not known&nbsp; Syncope</p><p>Eye disorders<br />Uncommon&nbsp; Vision blurred</p><p>Ear and labyrinth disorders<br />Uncommon&nbsp; Tinnitus</p><p>Vascular disorders</p><p>Uncommon Hypotension</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Uncommon&nbsp;Cough</p><p>Not known&nbsp; Non cardiogenic&nbsp; pulmonary oedema</p><p>Gastrointestinal disorders</p><p>Very rare Diarrhoea</p><p>Musculoskeletal and connective tissue disorders</p><p>Uncommon&nbsp;Myalgia</p><p>Very rare&nbsp;Arthralgia</p><p>Renal and urinary disorders</p><p>Not known&nbsp;Impaired renal function</p><p>General disorders and administration site conditions</p><p>Uncommon&nbsp;Fatigue</p><p>Investigations<br />Not known Serum uric acid increased, Serum bilirubin and Serum creatinine increased, Hypokalaemia, Hyponatraemia, Elevation of Blood Urea Nitrogen, Neutropenia</p><p>Additional information on the individual components Adverse reactions previously reported with one of the individual components may be potential undesirable effects with Arbiten Plus as well, even if not observed in clinical trials or during postmarketing period.</p><p>Table 2. Frequency of adverse reactions with valsartan<br />Blood and lymphatic system disorders</p><p>Not known Decrease in haemoglobin, decrease in haematocrit, thrombocytopenia</p><p>Immune system disorders<br />Not known Other hypersensitivity/allergic reactions including serum sickness<br />Metabolism and nutrition disorders<br />Not known Increase of serum potassium, hyponatraemia</p><p>Ear and labyrinth disorders</p><p>Uncommon Vertigo<br />Vascular disorders<br />Not known Vasculitis</p><p>Gastrointestinal disorders<br />Uncommon Abdominal pain<br />Hepatobiliary disorders<br />Not known Elevation of liver function values</p><p>Skin and subcutaneous tissue disorders</p><p>Not known Angioedema, rash, pruritus<br />Renal and urinary disorders<br />Not known Renal failure<br />Table 3. Frequency of adverse reactions with hydrochlorothiazide Hydrochlorothiazide has been extensively prescribed for many years, frequently in higher doses than those administered with Arbiten Plus. The following adverse reactions have been reported in patients treated with monotherapy of thiazide diuretics, including hydrochlorothiazide:<br />Blood and lymphatic system disorders</p><p>Rare&nbsp;Thrombocytopenia sometimes with purpura<br />Very rare Agranulocytosis, leucopenia, haemolytic anaemia, bone marrow failure<br />Not known&nbsp;Aplastic anemia<br />Immune system disorders<br />Very Rare Hypersensitivity reactions</p><p>Metabolism and nutrition disorders<br />Very common Hypokalaemia, blood lipids increased (mainly at higher doses)<br />Common Hyponatraemia, hypomagnesaemia, hyperuricaemia<br />Rare Hypercalcaemia, hyperglycaemia, glycosuria and worsening of&nbsp;diabetic metabolic state<br />Very rare Hypochloraemic alkalosis<br />Psychiatric disorders<br />Rare Depression, sleep disturbances<br />Nervous system disorders<br />Rare Headache, dizziness, paraesthesia<br />Eye disorders<br />Rare Visual impairment<br />Not known Acute angle-closure glaucoma<br />Cardiac disorders<br />Rare Cardiac arrhythmias<br />Vascular disorders<br />Common Postural hypotension<br />Respiratory, thoracic and mediastinal disorders<br />Very rare Respiratory distress including pneumonitis and pulmonary oedema</p><p>Gastrointestinal disorders<br />Common Loss of appetite, mild nausea and vomiting<br />Rare Constipation, gastrointestinal discomfort, diarrhoea<br />Very rare Pancreatitis<br />Hepatobiliary disorders<br />Rare Intrahepatic cholestasis or jaundice<br />Renal and urinary disorders<br />Not known Renal dysfunction, acute renal failure</p><p>Skin and subcutaneous tissue disorders<br />Common Urticaria and other forms of rash<br />Rare Photosensitisation<br />Very rare Necrotising vasculitis and toxic epidermal necrolysis, cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus<br />Not known Erythema multiforme<br />General disorders and administration site conditions<br />Not known Pyrexia, asthenia<br />Musculoskeletal and connective tissue disorders<br />Not known Muscle spasm</p><p>Reproductive system and breast disorders<br />Common Impotence<br />To reports any side effect(s):</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms</p><p>Overdose with valsartan may result in marked hypotension, which could lead to depressed level of consciousness, circulatory collapse and/or shock. In addition, the following signs and symptoms may occur due to an overdose of the hydrochlorothiazide component: nausea, somnolence, hypovolaemia, and electrolyte disturbances associated with cardiac arrhythmias and muscle spasms.</p><p>Treatment</p><p>The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms, stabilisation of the circulatory condition being of prime importance. If hypotension occurs, the patient should be placed in the supine position and salt and volume supplementation should be given rapidly.</p><p>Valsartan cannot be eliminated by means of haemodialysis because of its strong plasma binding behaviour whereas clearance of hydrochlorothiazide will be achieved by dialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists and diuretics, valsartan and diuretics; ATC Code: C09D A03</p><p>Valsartan/hydrochlorothiazide</p><p>Arbiten Plus 80/12.5 mg Film Coated Tablets only:</p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on hydrochlorothiazide 12.5 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (14.9/11.3 mmHg) compared to hydrochlorothiazide 12.5 mg (5.2/2.9 mmHg) and hydrochlorothiazide 25 mg (6.8/5.7 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (60%) compared to hydrochlorothiazide 12.5 mg (25%) and hydrochlorothiazide&nbsp;25 mg (27%).</p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on valsartan 80 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (9.8/8.2 mmHg) compared to valsartan 80 mg (3.9/5.1 mmHg) and valsartan 160 mg (6.5/6.2 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (51%) compared to valsartan 80 mg (36%) and valsartan 160 mg (37%).</p><p>In a double-blind, randomised, placebo-controlled, factorial design trial comparing various dose combinations of valsartan/hydrochlorothiazide to their respective components, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 80/12.5 mg (16.5/11.8 mmHg) compared to placebo (1.9/4.1 mmHg) and both hydrochlorothiazide 12.5 mg (7.3/7.2 mmHg) and valsartan 80 mg (8.8/8.6 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 80/12.5 mg (64%) compared to placebo (29%) and hydrochlorothiazide (41%).</p><p>Arbiten Plus 160/12.5 mg and 160/25mg Film Coated Tablets only:</p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on hydrochlorothiazide 12.5 mg, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/ hydrochlorothiazide 160/12.5 mg (12.4/7.5 mmHg) compared to hydrochlorothiazide 25 mg (5.6/2.1 mmHg). In addition, a significantly greater percentage of patients responded (BP &lt;140/90 mmHg or SBP reduction &ge;20 mmHg or DBP reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/12.5 mg (50%) compared to hydrochlorothiazide 25 mg (25%).</p><p>In a double-blind, randomised, active-controlled trial in patients not adequately controlled on valsartan 160 mg, significantly greater mean systolic/diastolic BP reductions were observed with both the combination of valsartan/hydrochlorothiazide 160/25 mg (14.6/11.9 mmHg) and valsartan/hydrochlorothiazide 160/12.5 mg (12.4/10.4 mmHg) compared to valsartan 160 mg (8.7/8.8 mmHg). The difference in BP reductions between the 160/25 mg and 160/12.5 mg doses also reached statistical significance. In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/25 mg (68%) and 160/12.5 mg (62%) compared to valsartan 160 mg (49%).</p><p>In a double-blind, randomised, placebo-controlled, factorial design trial comparing various dose combinations of valsartan/hydrochlorothiazide to their respective components, significantly greater mean systolic/diastolic BP reductions were observed with the combination of valsartan/hydrochlorothiazide 160/12.5 mg (17.8/13.5 mmHg) and 160/25 mg (22.5/15.3 mmHg) compared to placebo (1.9/4.1 mmHg) and the respective monotherapies, i.e., hydrochlorothiazide 12.5 mg (7.3/7.2 mmHg), hydrochlorothiazide 25 mg (12.7/9.3 mmHg) and valsartan 160 mg (12.1/9.4 mmHg). In addition, a significantly greater percentage of patients responded (diastolic BP &lt;90 mmHg or reduction &ge;10 mmHg) with valsartan/hydrochlorothiazide 160/25 mg (81%) and valsartan/hydrochlorothiazide 160/12.5 mg (76%) compared to placebo (29%) and the respective monotherapies, i.e.,&nbsp;hydrochlorothiazide 12.5 mg (41%), hydrochlorothiazide 25 mg (54%), and valsartan 160 mg (59%).</p><p>Arbiten Plus 80/12.5mg, 160/12.5 mg and 160/25mg Film Coated Tablets: Dose-dependent decreases in serum potassium occurred in controlled clinical studies with valsartan + hydrochlorothiazide. Reduction in serum potassium occurred more frequently in patients given 25 mg hydrochlorothiazide than in those given 12.5 mg hydrochlorothiazide. In controlled clinical trials with valsartan/hydrochlorothiazide the potassium lowering effect of hydrochlorothiazide was attenuated by the potassium-sparing effect of valsartan. Beneficial effects of valsartan in combination with hydrochlorothiazide on cardiovascular mortality and morbidity are currently unknown.</p><p>Epidemiological studies have shown that long-term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity. Valsartan Valsartan is an orally active and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. The increased plasma levels of Ang II following AT1 receptor blockade with valsartan may stimulate the unblocked AT2 receptor, which appears to counterbalance the effect of the AT1 receptor. Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000 fold) greater affinity for the AT1 receptor than for the AT2 receptor. Valsartan is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p><p>Valsartan does not inhibit ACE, also known as kininase II, which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (P &lt;0.05) lower in patients treated with valsartan than in those treated with an ACE inhibitor (2.6% versus 7.9% respectively). In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those receiving a thiazide diuretic experienced cough compared to 68.5% of those treated with an ACE inhibitor (P &lt;0.05).</p><p>Administration of valsartan to patients with hypertension results in reduction of blood pressure without affecting pulse rate. In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after dosing. During repeated dosing, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks and is sustained during long-term therapy. Combined with hydrochlorothiazide, a significant additional reduction in blood pressure is achieved.</p><p>Abrupt withdrawal of valsartan has not been associated with rebound hypertension or other adverse clinical events. In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80-160 mg/od) versus amlodipine (5-10 mg/od), in 332 type 2 diabetic&nbsp;patients (mean age: 58 years; 265 men) with microalbuminuria (valsartan: 58 &mu;g/min; amlodipine: 55.4 &mu;g/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120 &mu;mol/l). At 24 weeks, UAE was reduced (p &lt;0.001) by 42% (&ndash;24.2 &mu;g/min; 95% CI: &ndash;40.4 to &ndash;19.1) with valsartan and approximately 3% (&ndash;1.7 &mu;g/min; 95% CI: &ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups. The Diovan Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/88 mmHg) with type 2 diabetes, albuminuria (mean=102 &mu;g/min; 20&ndash;700 &mu;g/min) and preserved renal function (mean serum creatinine = 80 &mu;mol/l). Patients were randomised to one of 3 doses of valsartan (160, 320 and 640 mg/od) and treated for 30 weeks. The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage change in UAE was significantly reduced by 36% from baseline with valsartan 160 mg (95%CI: 22 to 47%), and by 44% with valsartan 320 mg (95%CI: 31 to 54%). It was concluded that 160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.</p><p>Hydrochlorothiazide</p><p>The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na+Cl- symporter perhaps by competing for the&nbsp;Cl-site, thereby affecting electrolyte reabsorption mechanisms:directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly by this diuretic action reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so with co-administration of valsartan the reduction in serum potassium is less pronounced as observed under monotherapy with hydrochlorothiazide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valsartan/hydrochlorothiazide</p><p>The systemic availability of hydrochlorothiazide is reduced by about 30% when co-administered with valsartan. The kinetics of valsartan are not markedly affected by the co-administration of hydrochlorothiazide. This observed interaction has no impact on the combined use of valsartan and hydrochlorothiazide, since controlled clinical trials have shown a clear anti-hypertensive effect, greater than that obtained with either active substance given alone, or placebo.</p><p>Valsartan</p><p>Absorption</p><p>Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2&ndash;4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically&nbsp;significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.</p><p>Distribution</p><p>The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94 &ndash; 97%), mainly serum albumin.</p><p>Biotransformation</p><p>Valsartan is not biotransformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.</p><p>Elimination</p><p>Valsartan shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.</p><p>Hydrochlorothiazide</p><p>Absorption</p><p>The absorption of hydrochlorothiazide, after an oral dose, is rapid (tmax about 2 h). The increase in mean AUC is linear and dose proportional in the therapeutic range. The effect of food on hydrochlorothiazide absorption, if any, has little clinical significance. Absolute bioavailability of hydrochlorothiazide is 70% after oral administration.</p><p>Distribution</p><p>The apparent volume of distribution is 4&ndash;8 l/kg. Circulating hydrochlorothiazide is bound to serum proteins (40&ndash;70%), mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at approximately 3 times the level in plasma.</p><p>Elimination</p><p>Hydrochlorothiazide is eliminated predominantly as unchanged drug. Hydrochlorothiazide is eliminated from plasma with a half-life averaging 6 to 15 hours in the terminal elimination phase. There is no change in the kinetics of hydrochlorothiazide on repeated dosing, and accumulation is minimal when dosed once daily. There is more than 95% of the absorbed dose being excreted as unchanged compound in the urine. The renal clearance is composed of passive filtration and active secretion into the renal tubule.</p><p>Special populations</p><p>Elderly</p><p>A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance. Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers.</p><p>Renal impairment</p><p>At the recommended dose of Arbiten Plus no dose adjustment is required for patients with a Glomerular Filtration Rate (GFR) of 30&ndash;70 ml/min.</p><p>In patients with severe renal impairment (GFR &lt;30 ml/min) and patients undergoing dialysis no data are available for Arbiten Plus. Valsartan is highly bound to plasma protein and is not to be removed by dialysis, whereas clearance of hydrochlorothiazide will be achieved by dialysis. In the presence of renal impairment, mean peak plasma levels and AUC values of hydrochlorothiazide are increased and the urinary excretion rate is reduced. In patients with mild to moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been observed. In patients with severe renal impairment an 8-fold increase in AUC has been observed. Hydrochlorothiazide is contraindicated in patients with severe renal impairment (see section 4.3).</p><p>Hepatic impairment</p><p>In a pharmacokinetics trial in patients with mild (n=6) to moderate (n=5) hepatic dysfunction, exposure to valsartan was increased approximately 2-fold compared with healthy volunteers (see sections 4.2 and 4.4). There is no data available on the use of valsartan in patients with severe hepatic dysfunction (see section 4.3). Hepatic disease does not significantly affect the pharmacokinetics of hydrochlorothiazide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The potential toxicity of the valsartan - hydrochlorothiazide combination after oral administration was investigated in rats and marmosets in studies lasting up to six months. No findings emerged that would exclude the use of therapeutic doses in man. The changes produced by the combination in the chronic toxicity studies are most likely to have been caused by the valsartan component. The toxicological target organ was the kidney, the reaction being more marked in the marmoset than the rat. The combination led to kidney damage (nephropathy with tubular basophilia, rises in plasma urea, plasma creatinine and serum potassium, increases in urine volume and urinary electrolytes from 30 mg/kg/day valsartan + 9 mg/kg/day hydrochlorothiazide in rats and 10 + 3 mg/kg/d in marmosets), probably by way of altered renal haemodynamics. These doses in rat, respectively, represent 0.9 and 3.5&ndash;times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m<sup>2&nbsp;</sup>&nbsp;basis. These doses in marmoset, respectively, represent 0.3 and 1.2&ndash;times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m<sup>2&nbsp;</sup>&nbsp;basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient.) High doses of the valsartan - hydrochlorothiazide combination caused falls in red blood cell indices (red cell count, haemoglobin, haematocrit, from 100 + 31 mg/kg/d in rats and 30 + 9 mg/kg/d in marmosets). These doses in rat, respectively, represent 3.0 and 12 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m<sup>2&nbsp;</sup>basis. These doses in marmoset, respectively, represent 0.9 and 3.5 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m2 basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient).</p><p>In marmosets, damage was observed in the gastric mucosa (from 30 + 9 mg/kg/d). The combination also led in the kidney to hyperplasia of the afferent aterioles (at 600 + 188 mg/kg/d in rats and from 30 + 9 mg/kg/d in marmosets). These doses in marmoset, respectively, represent 0.9 and 3.5 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m<sup>2&nbsp;</sup>basis. These doses in rat, respectively, represent 18 and 73 times the maximum recommended human dose (MRHD) of valsartan and hydrochlorothiazide on a mg/m<sup>2&nbsp;</sup>basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient). The above mentioned effects appear to be due to the pharmacological effects of high valsartan doses (blockade of angiotensin II-induced inhibition of renin release, with stimulation of the renin-producing cells) and also occur with ACE inhibitors. These findings appear to have no relevance to the use of therapeutic doses of valsartan in humans. The valsartan - hydrochlorothiazide combination was not tested for mutagenicity, chromosomal breakage or carcinogenicity, since there is no evidence of interaction between the two substances. However, these tests were performed separately with valsartan and hydrochlorothiazide, and produced no evidence of mutagenicity, chromosomal breakage or carcinogenicity.</p><p>In rats, maternally toxic doses of valsartan (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient). Similar findings were seen with valsartan/hydrochlorothiazide in rats and rabbits. In embryo-fetal development (Segment II) studies with valsartan/hydrochlorothiazide in rat and rabbit, there was no evidence of teratogenicity; however, fetotoxicity associated with maternal toxicity was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excipients of Arbiten plus Film Coated Tablet:<br />Microcrystalline Cellulose<br />Povidone K<br />Crospovidone</p><p>Sodium Lauryl Sulphate<br />Silicified Microcrystalline Cellulose (Prosolve)<br />Talc<br />Magnesium Stearate<br />Hydroxy Propyl Methyl Cellulose (HPMC) (Sepifilm LP)<br />Sepisperse Yellow 3050 (HPMC polymer and Yellow iron oxide)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arbiten Plus Film Coated Tablet shelf life is 3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Arbiten Plus Film Coated Tablet:<br />Primary Packaging Material: Aluminum / Aluminum blister pack<br />Secondary Packaging Material: Printed cardboard box containing the blister packs and the package insert.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jordan Sweden Medical and Sterilization Company (JOSWE-medical)
P.O. Box 851831 Amman 11185 Jordan
E-mail: joswe@go.com.jo
Tel: +962 6 5859765 - + 962 6 5728327
Fax: +962 6 5814526 - +962 6 5728326
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>